Takeda and HUTCHMED Announce New Drug Application (NDA) for Fruquintinib for Treatment of Previously Treated Metastatic Colorectal Cancer Granted Priority Review
— Prescription Drug User Fee Act (PDUFA) Target Action Date set for November 30, 2023…
News
Sekur Private Data Ltd. Releases Unaudited Financials and MDA for Q1 2023 – Sales Increase 50% Q1 2023 vs Q1 2022
Toronto, Ontario, and New York, New York–(Newsfile Corp. – May 25, 2023) – Sekur Private…
Sekur Private Data Ltd. Releases Unaudited Financials and MDA for Q1 2023 – Sales Increase 50% Q1 2023 vs Q1 2022
Toronto, Ontario, and New York, New York–(Newsfile Corp. – May 25, 2023) – Sekur Private…
MyndTec Inc. Completes Non-Brokered Private Placement
Mississauga, Ontario–(Newsfile Corp. – May 25, 2023) – MyndTec Inc. (CSE: MYTC) (“MyndTec” or the…
Bunzz Celebrates 10K User Milestone and Establishes Itself as a Leading Smart Contract Hub for DApp Development
SINGAPORE, May 26, 2023 – (ACN Newswire) – Bunzz, a smart contract development platform, recently…
Governor Newsom Visits Moxion Power as Company Announces Energy Storage Gigafactory in Richmond, CA
Moxion’s new facility will create 800 local manufacturing jobs and produce approximately 10,000 mobile energy…
Singapore-Based Global Schools Foundation Announces Strategic Partnership With Vikaasa Schools
SINGAPORE, May 26, 2023 – (ACN Newswire) – Singapore-based Global Schools Foundation (GSF) has announced…
Autonomous Mobile Robots by Synergy Dynamics (HK) Ltd Triumph in Warehouse Trials Across China
HONG KONG, May 26, 2023 – (ACN Newswire) – The successful testing period conducted by…
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Cutera, Inc. (CUTR) on Behalf of Investors
BENSALEM, Pa.–(BUSINESS WIRE)–Law Offices of Howard G. Smith announces an investigation on behalf of Cutera,…
Redfin Reports Mortgage Rates Surge Past 7.1% For First Time Since November; Some Buyers Back Off While Others Lower Budget
Monthly housing payments hit a new record high this week as mortgage rates jumped, pricing…
Flatiron Health Announces Research to be Presented at American Society of Clinical Oncology 2023 Annual Meeting
NEW YORK–(BUSINESS WIRE)–Flatiron Health today announced that the company and its collaborators will present a…
Vahanna Tech Edge Acquisition I Corp. Announces Additional Contribution to Trust Account to Extend Deadline to Consummate Business Combination
NEW YORK–(BUSINESS WIRE)–Vahanna Tech Edge Acquisition I Corp. (NASDAQ: VHNAU, VHNA, VHNAW) (“Vahanna” or the…
HUTCHMED Highlights Presentations at the 2023 ASCO Annual Meeting
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., May 25, 2023 (GLOBE NEWSWIRE) —…
HUTCHMED Highlights Presentations at the 2023 ASCO Annual Meeting
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., May 25, 2023 (GLOBE NEWSWIRE) —…
BioSyent Declares Second Quarter 2023 Dividend
MISSISSAUGA, Ontario, May 25, 2023 (GLOBE NEWSWIRE) — BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture:…
BioSyent Declares Second Quarter 2023 Dividend
MISSISSAUGA, Ontario, May 25, 2023 (GLOBE NEWSWIRE) — BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture:…
Zentalis Announces Presentation of Positive Phase 1b Data Demonstrating Durable Responses and Favorable Safety Profile of Azenosertib in Combination with Chemotherapy at the 2023 ASCO Annual Meeting
Strong anti-tumor activity shown in a platinum-resistant ovarian cancer population, with a confirmed ORR of…
Zentalis Announces Presentation of Positive Phase 1b Data Demonstrating Durable Responses and Favorable Safety Profile of Azenosertib in Combination with Chemotherapy at the 2023 ASCO Annual Meeting
Strong anti-tumor activity shown in a platinum-resistant ovarian cancer population, with a confirmed ORR of…
Theratechnologies to Present Preliminary Safety and Efficacy Data from Phase 1 Trial of Sudocetaxel Zendusortide in Heavily Pretreated Cancer Patients at ASCO 2023
Preliminary signs of antitumor activity noted in 36% of patients, with two partial responses (PR)…
Theratechnologies to Present Preliminary Safety and Efficacy Data from Phase 1 Trial of Sudocetaxel Zendusortide in Heavily Pretreated Cancer Patients at ASCO 2023
Preliminary signs of antitumor activity noted in 36% of patients, with two partial responses (PR)…